Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave's HPV Tests To Use Agencourt Bioscience's Sample-Prep System

NEW YORK (GenomeWeb News) - Beckman Coulter subsidiary Agencourt Bioscience said today that Third Wave Technologies will use its Genfind DNA-isolation system for two human papillomavirus tests that it expects to market in 2009.
Third Wave, now a wholly owned subsidiary of Hologic, submitted its Cervista HPV HR and Cervista HPV 16/18 tests to the US Food and Drug Administration for pre-market approval in April.
The companies said that they are also collaborating on the development of “future applications” for Agencourt’s nucleic acid preparation technology, but did not provide further details of their plans.
Genfind is based on Agencourt’s Solid Phase Reversible Immobilization paramagnetic bead-based nucleic acid purification technology, which eliminates the need for solvents, vacuum filtration, or centrifugation steps, the company said.
Kevin Conroy, president and CEO of Third Wave, said in a statement that Agencourt’s Genfind technology delivers “reliable high recovery of purified DNA” and is easily automated.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.